MedTrace Logo

Short Duration Levetiracetam to Extended Course for Seizure Prophylaxis After aSAH

NCT01137110 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 84

Last updated 2019-07-12

Study results available
· View outcomes & findings →

Summary

Our primary objective is to compare two treatment options for prevention of seizures following a subarachnoid hemorrhage and determine if a short-course regimen of levetiracetam is as efficacious in the prevention of in-hospital seizures when compared to an extended course.

Conditions

  • Subarachnoid Hemorrhage

Interventions

OTHER

Brief LEV

Levetiracetam 1000mg BID x 3 days for prophylaxis

OTHER

Extended LEV

Levetiracetam 1000mg BID for length of hospital stay for prophylaxis

Sponsors & Collaborators

  • Washington University School of Medicine

    lead OTHER

Principal Investigators

  • Theresa Human-Murphy · Barnes-Jewish Hospital, Washington University

Study Design

Allocation
RANDOMIZED
Purpose
PREVENTION
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
99 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2010-05-01
Primary Completion
2013-01-01
Completion
2017-01-01

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01137110 on ClinicalTrials.gov